ENHANCED BOTROCETIN-INDUCED TYPE-IIB VONWILLEBRAND-FACTOR BINDING TO PLATELET GLYCOPROTEIN-IB INITIATES HYPERAGGLUTINATION OF NORMAL PLATELETS

Botrocetin, a protein isolated from the venom of the snake Bothrops jararaca, induces platelet aggregation/agglutination by von Willebrand factor (vWF) binding to the membrane glycoprotein (GP) Ib, an action resembling that of ristocetin. However, some differences in the interaction between vWF and platelet GPIb induced by these two substances have been reported. We have recently shown that the GPIb binding domain on the vWF molecule, in both instances, resides in the tryptic 52/48 kDa fragment extending from amino acid residue 449 to 728 of the constituent subunit. In the present report, we demonstrate that botrocetin does not induce agglutination of formalin‐fixed platelets from a patient with Bernard‐Soulier syndrome congenitally lacking GPIb and GPIX as well as GPV, a finding similar to that shown with ristocetin. A monoclonal antibody against GPIb (AP‐1) inhibits either ristocetin‐ or botrocetin‐dependent vWF binding to formalin‐fixed platelets from normal individuals. Therefore, botrocetin‐induced vWF binding to formalin‐fixed platelets may reflect the interaction between vWF and platelet GPIb. To strengthen this concept, we have now found that heightened botrocetin‐induced type IIB vWF binding to platelet GPIb causes hyperagglutination of normal platelets. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company